278 related articles for article (PubMed ID: 26241803)
1. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus infection and nasopharyngeal carcinoma.
Tsao SW; Tsang CM; Lo KW
Philos Trans R Soc Lond B Biol Sci; 2017 Oct; 372(1732):. PubMed ID: 28893937
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells.
Lo AK; Lo KW; Ko CW; Young LS; Dawson CW
J Pathol; 2013 Jul; 230(3):336-46. PubMed ID: 23592276
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus in the pathogenesis of NPC.
Raab-Traub N
Semin Cancer Biol; 2002 Dec; 12(6):431-41. PubMed ID: 12450729
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
[TBL] [Abstract][Full Text] [Related]
6. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.
Tsang CM; Tsao SW
Virol Sin; 2015 Apr; 30(2):107-21. PubMed ID: 25910483
[TBL] [Abstract][Full Text] [Related]
7. NF-κB Signaling Regulates Expression of Epstein-Barr Virus BART MicroRNAs and Long Noncoding RNAs in Nasopharyngeal Carcinoma.
Verhoeven RJ; Tong S; Zhang G; Zong J; Chen Y; Jin DY; Chen MR; Pan J; Chen H
J Virol; 2016 Jul; 90(14):6475-88. PubMed ID: 27147748
[TBL] [Abstract][Full Text] [Related]
8. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
9. Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma.
Tao Y; Shi Y; Jia J; Jiang Y; Yang L; Cao Y
Expert Rev Mol Med; 2015 Aug; 17():e15. PubMed ID: 26282825
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma.
Masmoudi A; Toumi N; Khanfir A; Kallel-Slimi L; Daoud J; Karray H; Frikha M
Cancer Treat Rev; 2007 Oct; 33(6):499-505. PubMed ID: 17544585
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
12. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
13. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
14. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression.
Ma N; Kawanishi M; Hiraku Y; Murata M; Huang GW; Huang Y; Luo DZ; Mo WG; Fukui Y; Kawanishi S
Int J Cancer; 2008 Jun; 122(11):2517-25. PubMed ID: 18307254
[TBL] [Abstract][Full Text] [Related]
15. Viral Carcinogenesis Beyond Malignant Transformation: EBV in the Progression of Human Cancers.
Elgui de Oliveira D; Müller-Coan BG; Pagano JS
Trends Microbiol; 2016 Aug; 24(8):649-664. PubMed ID: 27068530
[TBL] [Abstract][Full Text] [Related]
16. The interplay of host genetic factors and Epstein-Barr virus in the development of nasopharyngeal carcinoma.
Lung ML; Cheung AK; Ko JM; Lung HL; Cheng Y; Dai W
Chin J Cancer; 2014 Nov; 33(11):556-68. PubMed ID: 25367335
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
18. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells.
Lo AK; Dawson CW; Young LS; Ko CW; Hau PM; Lo KW
J Pathol; 2015 Oct; 237(2):238-48. PubMed ID: 26096068
[TBL] [Abstract][Full Text] [Related]
19. STAT3 as a therapeutic target for Epstein-Barr virus (EBV): associated nasopharyngeal carcinoma.
Ho Y; Tsao SW; Zeng M; Lui VW
Cancer Lett; 2013 Apr; 330(2):141-9. PubMed ID: 23220625
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
